Table 1.
FDA-approved ADCs
| Drug name | Approval year | Indication(s) |
|---|---|---|
| GO (trade name: Mylotarg) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf |
2017; 2000 | Newly diagnosed and relapsed CD33-positive acute myeloid leukemia (AML) |
| Brentuximab vedotin (trade name: Adcetris) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125388s099lbl.pdf |
2011 | Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL) |
| Ado-trastuzumab emtansine (trade name: Kadcyla) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf |
2013 | HER2-positive, metastatic breast cancer and the adjuvant treatment of patients with HER2-positive early breast cancer |
| Inotuzumab ozogamicin (trade name: Besponsa) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf |
2017 | Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia |
| Polatuzumab vedotin-piiq (trade name: Polivy) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf |
2019 | Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) |
| Enfortumab vedotin (trade name: Padcev) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf |
2019 | Locally advanced or metastatic urothelial cancer |
| Trastuzumab deruxtecan (trade name: Enhertu) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf |
2019 | Unresectable or metastatic HER2-positive breast cancer |
| Sacituzumab govitecan (trade name: Trodelvy) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf |
2020 | Metastatic triple-negative breast cancer (mTNBC) |
| Belantamab mafodotin-blmf (trade name: Blenrep) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf |
2020 | Relapsed or refractory multiple myeloma |